

LAHIVE
&
COCKFIELD
L L P

COUNSELLORS AT LAW
28 STATE STREET
BOSTON, MASSACHUSETTS 02109-1784
TELEPHONE (617) 227-7400
FAX (617) 742-4214
lc@lahive.com



JOHN A. LAHIVE, JR. (1926-1997)
THOMAS V. SMURZYNSKI
GIULIO A. DeCONTI, JR.
ELIZABETH A. HANLEY
AMY BAKER MANDRAGOURAS
ANTHONY A. LAURENTANO
KEVIN J. CANNING
JANE E. REMILLARD
DeANN F. SMITH
DEBRA J. MILASINCIC, Ph.D.
WILLIAM A. SCOFIELD, Jr.
SIBLEY P. REPPERT
DAVID R. BURNS
JOHN S. CURRAN
SEAN D. DETWEILER
MEGAN E. WILLIAMS, Ph.D.
HATHAWAY P. RUSSELL *
MARIA LACOTRIPE ZACHARAKIS,
Ph.D.

DANIELLE L. HERRITT
EUIHOON LEE **
MANEESH GULATI
CYNTHIA M. SOROS
PETER W. DINI, Ph.D.
MICHAEL J. BASTIAN, Ph.D.
CHRISTOPHER J. MCKENNA
VINCENT P. LOCCISANO
JAMES M. MCKENZIE

SENIOR COUNSEL
JAMES E. COCKFIELD

OF COUNSEL
JEREMIAH LYNCH
JEANNE M. DIGIORGIO
CYNTHIA L. KANIK, Ph.D.
JOHN D. LANZA

PATENT AGENTS

JONATHAN M. SPARKS, Ph.D.
ANDRINA WILLIAMS ZINK
CRISTIN E. HOWLEY, Ph.D.
JILL A. MELLO, Ph.D.
CHRISTOPHER E. DRABIK
JAMES H. VELEMA

TECHNICAL SPECIALISTS

CATHERINE M. BISHOP
JACOB G. WEINTRAUB
DEBORAH L. NAGLE, Ph.D.
A. JACQUELINE WIZEMAN, Ph.D.
BRIAN C. TRINQUE, Ph.D.
CHRISTOPHER R. COWLES, Ph.D.
W. ELANA WANG
CYNTHIA M. GILBERT
MEAGHAN L. RICHMOND, Ph.D.

* Admitted in TX only
** Admitted in CT only

December 15, 2004

Christopher J. Nichols, PhD
United State Patent & Trademark Office
Technology Art Unit 1647
Crystal Plaza II
Lobby Room 1B03
Arlington VA, 22202

Re: U.S. Patent Application No.: 10/010,942
For: *HUMANIZED ANTIBODIES THAT RECOGNIZE BETA AMYLOID
PEPTIDE*
Inventors: Guriq Basi, *et al.*
Filed: December 6, 2001
Our Ref. No.: ELN-002

Dear Sir:

I enclose herewith for filing in the above-identified application the following:

1. Supplemental Information Disclosure Statement;
2. PTO Form SB/08;
3. Copies of references cited in PTO Form SB/08 (45); and
4. A Return Postcard.

No additional costs are believed to be due in connection with the filing of this Supplemental Information Disclosure Statement. However, please charge any other necessary fees due in connection with the enclosed statement to our Deposit Order Account No. 12-0080. For this purpose, a duplicate of this sheet is attached.

Respectfully submitted,
LAHIVE & COCKFIELD LLP

Debra J. Milasincic, Esq.
Registration No. 46,931
Attorney for Applicants



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of: Guriq Basi, *et al.*

Serial No.: 10/010,942

Filed: December 6, 2001

For: *HUMANIZED ANTIBODIES THAT
RECOGNIZE BETA AMYLOID PEPTIDE*

Attorney Docket No.: ELN-002

Group Art Unit: 1647

Examiner: Christopher J. Nichols

Christopher J. Nichols, PhD
United State Patent & Trademark Office
Technology Art Unit 1647
Crystal Plaza II
Lobby Room 1B03
Arlington VA, 22202

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Applicants and their Attorney are aware of the following additional publications, listed on the attached PTO Form SB/08, and in accordance with 37 CFR §1.97 hereby submit these publications for the Examiner's consideration. A copy of each cited publication is enclosed.

This statement is not to be interpreted as a representation that the cited publications are material, that an exhaustive search has been conducted, or that no other relevant information exists. Nor shall the citation of any publication herein be construed *per se* as a representation that such publication is prior art. Moreover, the Applicants understand that the Examiner will make an independent evaluation of the cited publications.

In accordance with 37 CFR §1.97(c)(2) and §1.17(p), please charge the \$180.00 submission fee to our Deposit Order Account No. 12-0080. Please charge any necessary additional fees or credit any overpayments to our Deposit Order Account No. 12-0080.

Respectfully submitted,



LAHIVE & COCKFIELD, LLP

Debra J. Milasincic, Esq.
Registration No. 46,931
Attorney for Applicants
28 State Street
Boston, MA 02109
(617) 227-7400

Date: December 15, 2004

AEM/DJM/JHV/rl
Enclosures



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Guriq Basi
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	1	of	3	Attorney Docket Number	ELN-002


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	548	Anderson, J.P., <i>et al.</i> Exact cleavage site of Alzheimer amyloid precursor in neuronal PC-12 cells." <i>Neurosci Lett.</i> 1991 Jul 8; 128(1):126-8.		
	549	Anderson, M.W. "Amending the amyloid hypothesis." <i>The Scientist.</i> 2004 Oct 25; 18(20).		
	550	Bacskai, B.J., <i>et al.</i> "Imaging of amyloid- β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy." <i>Nat Med.</i> 2001 Mar; 7(3):369-72.		
	551	Bacskai, B.J., <i>et al.</i> "Non-Fc-mediated mechanisms are involved in clearance of amyloid- β in vivo by immunotherapy." <i>J Neurosci.</i> 2002 Sep 15; 22(18):7873-8.		
	552	Check, E. "Battle of the mind." <i>Nature.</i> 2003 Mar 27; 422(6930):370-2.		
	553	Chromy, B.A., <i>et al.</i> "Self-assembly of A β (1-42) into globular neurotoxins." <i>Biochemistry.</i> 2003 Nov 11; 42(44):12749-60.		
	554	Citron, M., <i>et al.</i> "Evidence that the 42- and 40-amino acid forms of amyloid- β protein are generated from the β -amyloid precursor protein by different protease activities." <i>Proc Natl Acad Sci USA.</i> 1996 Nov 12; 93(23):13170-5.		
	555	Citron, M. "Alzheimer's disease: treatments in discovery and development." <i>Nat Neurosci.</i> 2002 Nov; 5:1055-7.		
	556	DeMattos, R.B., <i>et al.</i> "Brain to plasma amyloid- β efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease." <i>Science.</i> 2002 Mar 22; 295(5563):2264-7.		
	557	DeMattos, R.B., <i>et al.</i> "Peripheral anti-A β antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer's disease." <i>Proc Natl Acad Sci USA.</i> 2001 Jul 17; 98(15):8850-5.		
	558	Dodart, J-C., <i>et al.</i> "Immunization reverses memory deficits without reducing brain A β burden in Alzheimer's disease model." <i>Nat Neurosci.</i> 2002 May; 5(5):452-7.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--




PTO/SB/08a/b (08-03)
 Approved for use through 07/31/2006. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Guriq Basi
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	2	of	3	Attorney Docket Number	ELN-002

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	559	Dodel, R.C., et al. "Immunotherapy for Alzheimer's disease." <i>Lancet Neurol.</i> 2003 Apr; 2(4):215-20.		
	560	Dovey, H.F., et al. "Functional gamma-secretase inhibitors reduce beta-amyloid peptide levels in brain." <i>J Neurochem.</i> 2001 Jan; 76(1):173-81.		
	561	Duff, K., et al. "Increased amyloid- β 42(43) in brains of mice expressing mutant presenilin 1." <i>Nature.</i> 1996 Oct 24; 383(6602):710-3.		
	562	Eriksen, J.L., et al. "NSAIDs and enantiomers of flurbiprofen target γ -secretase and lower A β 42 in vivo." <i>J Clin Invest.</i> 2003 Aug; 112(3):440-9.		
	563	Findeis, M.A. "Approaches to discovery and characterization of inhibitors of amyloid β -peptide polymerization." <i>Biochim Biophys Acta.</i> 2000 Jul 26; 1502(1):76-84.		
	564	Frenkel, D., et al. "Reduction of β -amyloid plaques in brain of transgenic mouse model of Alzheimer's disease by EFRH-phage immunization." <i>Vaccine.</i> 2003 Mar 7; 21(11-12):1060-5.		
	565	Frenkel, D., et al. "Towards Alzheimer's β -amyloid vaccination." <i>Biologicals.</i> 2001 Sep-Dec; 29(3-4):243-7.		
	566	Gelinas, D.S., et al. "Immunotherapy for Alzheimer's disease." <i>Proc Natl Acad Sci USA.</i> 2004 Oct 5; 101 Suppl 2:14657-62.		
	567	Gong, Y., et al. "Alzheimer's disease-affected brain: presence of oligomeric A β ligands (ADDLs) suggests a molecular basis for reversible memory loss." <i>Proc Natl Acad Sci USA.</i> 2003 Sep 2; 100(18):10417-22.		
	568	Greenberg, S.M., et al. "Alzheimer disease's double-edged vaccine." <i>Nat Med.</i> 2003 Apr; 9(4):389-90.		
	569	Haass, C. "New hope for Alzheimer disease vaccine." <i>Nat Med.</i> 2002 Nov; 8(11):1195-6.		
	570	Hock, C., et al. "Generation of antibodies specific for β -amyloid by vaccination of patients with Alzheimer disease." <i>Nat Med.</i> 2002 Nov; 8(11):1270-5.		
	571	Irizarry, M.C., et al. "Alzheimer disease therapeutics." <i>J Neuropathol Exp Neurol.</i> 2001 Oct; 60(10):923-8.		
	572	Janus, C., et al. "Transgenic mouse models of Alzheimer's disease." <i>Physiol Behav.</i> 2001 Aug; 73(5):873-86.		
	573	Klein, W.L., et al. "Targeting small A β oligomers: the solution to an Alzheimer's disease conundrum?" <i>Trends Neurosci.</i> 2001 Apr; 24(4):219-24.		
	574	Mattson, M.P., et al. "Good and bad amyloid antibodies." <i>Science.</i> 2003 Sep 26; 301(5641):1847-9.		
	575	McLaurin, J., et al. "Therapeutically effective antibodies against amyloid- β peptide target amyloid- β residues 4-10 and inhibit cytotoxicity and fibrillogenesis." <i>Nat Med.</i> 2002 Nov; 8(11):1263-9. Epub 2002 Oct 15.		
	576	Monsonogo, A., et al. "Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease." <i>J Clin Invest.</i> 2003 Aug; 112(3):415-22.		
	577	Monsonogo, A., et al. "Immunotherapeutic approaches to Alzheimer's disease." <i>Science.</i> 2003 Oct 31; 302(5646):834-8.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--



PTO/SB/08a/b (08-03)
 Approved for use through 07/31/2006. OMB 0651-0031
 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/010,942
				Filing Date	December 6, 2001
				First Named Inventor	Guriq Basi
				Art Unit	1647
				Examiner Name	Christopher J. Nichols
Sheet	3	of	3	Attorney Docket Number	ELN-002

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	578	Paganetti, P.A., <i>et al.</i> "Amyloid precursor protein truncated at any of the γ -secretase sites is not cleaved to β -amyloid." <i>J Neurosci Res.</i> 1996 Nov 1; 46(3):283-93.		
	579	Pallitto, M.M., <i>et al.</i> "Recognition sequence design for peptidyl modulators of β -amyloid aggregation and toxicity." <i>Biochemistry.</i> 1999 Mar 23; 38(12):3570-8.		
	580	Pfeifer, M., <i>et al.</i> "Cerebral hemorrhage after passive anti-A β immunotherapy." <i>Science.</i> 2002 Nov 15; 298(5597):1379.		
	581	Schmid, R.E. "Study suggests Alzheimer vaccine fix." www.msnbc.com/news . 2002; 1-5.		
	582	Selkoe, D.J. "Alzheimer's disease is a synaptic failure." <i>Science.</i> 2002 Oct 25; 298(5594):789-91.		
	583	Sigurdsson, E.M., <i>et al.</i> "Immunization with a nontoxic/nonfibrillar amyloid- β homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice." <i>Am J Pathol.</i> 2001 Aug; 159(2):439-47.		
	584	Solomon, B., <i>et al.</i> "Generation and brain delivery of anti-aggregating antibodies against β -amyloid plaques using phage display technology." <i>J Neural Transm Suppl.</i> 2002; (62):321-5.		
	585	Solomon, B. "Immunotherapeutic strategies for prevention and treatment of Alzheimer's disease." <i>DNA Cell Biol.</i> 2001 Nov; 20(11):697-703.		
	586	White, A.R., <i>et al.</i> "Immunotherapy as a therapeutic treatment for neurodegenerative disorders." <i>J Neurochem.</i> 2003 Nov; 87(4):801-8.		
	587	Nicoll, J.A., <i>et al.</i> "Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report." <i>Nat Med.</i> 2003 Apr; 9(4):448-52.		
	588	Pan, W., <i>et al.</i> "Antibodies to β -amyloid decrease the blood-to-brain transfer of β -amyloid peptide." <i>Exp Biol Med</i> (Maywood). 2002 Sep; 227(8):609-15.		
	589	Sergeant, N., <i>et al.</i> "Truncated beta-amyloid peptide species in pre-clinical Alzheimer's disease as new targets for the vaccination approach." <i>J Neurochem.</i> 2003 Jun; 85(6):1581-91.		
	590	Walsh, D.M., <i>et al.</i> "Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo." <i>Nature.</i> 2002 Apr 4; 416(6880):535-9.		
	591	Washington University in St. Louis School of Medicine. "Study Gives Clues to Working of Anti-Alzheimer Antibody." Retrieved from internet www.medicine.wustl.edu/~wumpa/news , December 15, 2004.		
	592	"Researchers Develop Blood Test to Diagnose Alzheimer's-Type Changes in Mice." Retrieved from internet www.businesswire.com , December 15, 2004.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--